menu search

Xencor to present preclinical data from novel xmab® cd28 bispecific antibody programs at the american association for cancer research annual meeting 2023

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokin...

March 14, 2023, 4:31 pm

Eliem therapeutics reports fourth quarter and year-end financial results and business highlights

Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel ope...

March 6, 2023, 9:10 pm

Immuneering presents preclinical data with lead program imm-1-104 supporting universal-ras activity

Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-...

March 5, 2023, 11:30 pm

Verve therapeutics reports new preclinical data demonstrating potent and durable editing of angptl3 gene with verve-201 in wild-type and ldlr-deficient non-human primates

VERVE-201 preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homoz...

March 3, 2023, 11:30 am

Molecular partners presents new preclinical data supporting its radio darpin therapy platform

Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other ti...

February 28, 2023, 6:15 am

Why is neximmune (nexi) stock up 65% today?

NexImmune (NASDAQ: NEXI ) stock is rocketing higher on Thursday following the release of positive preclinical<...

February 16, 2023, 9:26 am

Wellbeing digital sciences caffeine replacement product boosted by preclinical study

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) told investors its subsidiary KGK Science Inc (KGK) has completed ...

February 15, 2023, 9:18 am

Sensei biotherapeutics to present new preclinical data for sns-101, a conditionally active vista-blocking antibody, at the keystone symposia on next generation antibody therapeutics

BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and develop...

February 14, 2023, 7:30 am

Salarius pharmaceuticals to present sp-3164 targeted protein degrader preclinical data at the inaugural molecular glue drug development summit

Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational New Drug appl...

January 19, 2023, 1:30 pm

Salarius pharmaceuticals to present sp-3164 targeted protein degrader preclinical data at the inaugural molecular glue drug development summit

Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models...

January 19, 2023, 8:30 am

Molecular partners initiates clinical study of trispecific candidate mp0533 for the treatment of acute myeloid leukemia

Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cells...

January 16, 2023, 6:00 am

Nurix therapeutics advances promising targeted protein modulation pipeline and outlines 2023 strategic priorities

Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase pl...

January 9, 2023, 1:35 pm

Opus genetics announces acquisition of the rights to two gene therapy product candidates for inherited retinal diseases

Opus to advance preclinical development programs for BEST1– and RHO-related retinal diseases Deal exp...

December 28, 2022, 1:00 pm

Genprex boosts its diabetes gene therapy program with the license of additional technology from the university of pittsburgh

Genprex, Inc. (NASDAQ:GNPX) revealed that it has struck an agreement with the University of Pittsburgh for a worldwide, exclusive license to some pat...

December 15, 2022, 9:16 am

Ngm bio gives presentation featuring preclinical characterization of ngm936 at 2022 ash annual meeting

–NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells whi...

December 13, 2022, 12:00 am

Molecular partners presents new preclinical data supporting its mp0533 darpin t-cell engager for the treatment of aml

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resu...

December 13, 2022, 12:00 am

Vincerx pharma presents preclinical data on vip943 in acute myeloid leukemia models at the 64th american society of hematology annual meeting 2022

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with sign...

December 11, 2022, 3:05 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm


Search within

Pages Search Results: